CoChat

Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial

Gilbert, Matthew P., Bain, Stephen C., Franek, Edward, Jodar-Gimeno, Esteban, Nauck, Michael A., Pratley, Richard, Réa, Rosângela Roginski, Kerr Saraiva, José Francisco, Rasmussen, Søren, Tornøe, Karen, von Scholten, Bernt Johan, Buse, John B., and the LEADER Publication Committee on behalf of the LEADER Trial Investigators* · 2019 · Annals of Internal Medicine
Cited by 62

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Letters19 March 2019Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled TrialMatthew P. Gilbert, DO, MPH, Stephen C. Bain, MD, Edward Franek, MD, PhD, Esteban Jodar-Gimeno, MD, PhD, Michael A. Nauck, MD, Richard Pratley, MD, Rosângela Roginski Réa, MD, José Francisco Kerr Saraiva, MD, PhD, Søren Rasmussen, MSc, PhD, Karen Tornøe, MD, PhD, Bernt Johan von Scholten, MD, DMSc, and John B. Buse, MD PhD, and the LEADER Publication Committee on behalf of the LEADER Trial Investigators*Matthew P. Gilbert, DO, MPHLarner College of Medicine at The University of Vermont, South Burlington, Vermont (M.P.G.), Stephen C. Bain, MDInstitute of Life Science, Swansea University Medical School, Singleton Hospital, Swansea, United Kingdom (S.C.B.), Edward Franek, MD, PhDMossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland (E.F.), Esteban Jodar-Gimeno, MD, PhDQuirónsalud Madrid and Ruber Juan Bravo University Hospitals, Universidad Europea de Madrid, Madrid, Spain (E.J.), Michael A. Nauck, MDDiabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University of Bochum, Bochum, Germany (M.A.N.), Richard Pratley, MDFlorida Hospital Diabetes Institute, Florida Hospital Translational Research Institute for Metabolism and Diabetes, Orlando, Florida (R.P.), Rosângela Roginski Réa, MDHospital de Clínicas da Universidade Federal do Paraná, Curitiba, Brazil (R.R.R.), José Francisco Kerr Saraiva, MD, PhDPontifícia Universidade Católica de Campinas, Campinas, Brazil (J.F.K.), Søren Rasmussen, MSc, PhDNovo Nordisk A/S, Søborg, Denmark (S.R., K.T., B.J.V.), Karen Tornøe, MD, PhDNovo Nordisk A/S, Søborg, Denmark (S.R., K.T., B.J.V.), Bernt Johan von Scholten, MD, DMScNovo Nordisk A/S, Søborg, Denmark (S.R., K.T., B.J.V.), and John B. Buse, MD PhDDiabetes Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina (J.B.B.), and the LEADER Publication Committee on behalf of the LEADER Trial Investigators*Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-1569 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Comorbidities and complications associated with type 2 diabetes mellitus (T2DM) increase with age, making treatment of elderly persons with this condition challenging. Clinical data on the effect of antihyperglycemic treatment on cardiovascular (CV) events in elderly persons are limited (1). The U.S. Food and Drug Administration and European Medicines Agency recommend collecting comprehensive data on elderly patients with diabetes, particularly those aged 75 years or older, to inform appropriate treatment of this growing population (2, 3).Glucagon-like peptide-1 agonists are among the newer classes of antihyperglycemic agents recommended to treat T2DM because they have high glycemic efficacy and low ...References1. American Diabetes Association. 11. Older adults: standards of medical care in diabetes—2018. Diabetes Care. 2018;41:S119-25. [PMID: 29222382] doi:10.2337/dc18-S011 CrossrefMedlineGoogle Scholar2. U.S. Department of Health and Human Services; U.S. Food and Drug Administration; Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research. Guidance for industry. E7 studies in support of special populations: geriatrics—questions and answers. 2012. Accessed at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM189544.pdf on 18 September 2018. Google Scholar3. Committee for Human Medicinal Products. Adequacy of guidance on the elderly regarding medicinal products for human use. European Medicines Agency. 2006. Accessed at www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500049541.pdf on 18 September 2018. Google Scholar4. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-9. [PMID: 25538310] doi:10.2337/dc14-2441 CrossrefMedlineGoogle Scholar5. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al; LEADER Steering Committee. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22. [PMID: 27295427] doi:10.1056/NEJMoa1603827 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Larner College of Medicine at The University of Vermont, South Burlington, Vermont (M.P.G.)Institute of Life Science, Swansea University Medical School, Singleton Hospital, Swansea, United Kingdom (S.C.B.)Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland (E.F.)Quirónsalud Madrid and Ruber Juan Bravo University Hospitals, Universidad Europea de Madrid, Madri

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/m18-1569

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Gilbert, M. P., Bain, S. C., Franek, E., Jodar-Gimeno, E., Nauck, M. A., Pratley, R., Réa, R. R., Kerr Saraiva, J. F., Rasmussen, S., Tornøe, K., von Scholten, B. J., Buse, J. B., & and the LEADER Publication Committee on behalf of the LEADER Trial Investigators*
Venue
Annals of Internal Medicine
Published
2019-03-19
Volume
170
Issue
6
Pages
423-426
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2902718472
Cited by
62
References
2
FWCI
3.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.